Complement 3 Glomerulopathy Market Outlook 2025-2035: The 7 major complement 3 glomerulopathy market reached a value of USD 9.3 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach ...

Because time to relapse was similar between the two treatments, the researchers said cyclophosphamide came out on top as the ...

Eleva, a German biopharmaceutical company, and 3PBIOVIAN, a global contract development and manufacturing organization (CDMO) ...

Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 ...

Eleva, a pioneer in unlocking biologics based on a breakthrough manufacturing platform, and 3PBIOVIAN, a contract development ...

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

Swiss pharma giant Novartis NVS reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges) of $1.98 per ...

which along with PNH and IgAN include atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathy (C3G), and idiopathic membranous nephropathy (IMN). It still has a long way to go to reach that ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, and 3PBIOVIAN, a leading contract development and manufacturing organization (CDMO), ...